The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
MAJWandCo, I think you're getting carried away suggesting that you profit from every successful short.
RCGH - I bought under 50p and sold at 234p, then bought back on the drop below 120p. I ended up taking a 20% loss due to misleading Google Ads and news articles funded by crooks in Balkan. So, we both made money on this stock, regardless of our positions.
I've invested in many successful stocks, like HE1 where I made 300% profit. Don't assume you're always right.
Please note, most people on LSE won't engage with negativity from derampers or shorters. However, it's important to hear both sides of an investment story.
Remember, nobody wins all the time. Don't gloat about your successes on LSE boards.
No worries! It's my money, and I'll keep buying more until the big news breaks!
Renalytix has received an unexpected approach from a large, publicly listed diagnostics company interested in acquiring them.
✅Formal Sale Process Launched: The company is now reviewing a potential sale of the company or its assets. They've initiated a Formal Sale Process to find the best strategic option for shareholders. This process will consider multiple potential buyers.
These are large transactions (sizable blocks of shares) executed outside of the regular stock exchange. They're often arranged privately between institutional investors to minimize market impact. These trades might not be reported immediately, leaving other traders unaware of the significant shift of ownership.
AstraZeneca, a major multinational pharmaceutical company, and Renalytix Plc, a kidney diagnostics company, have a significant connection. Here's the breakdown:
Partnership
✔️ AstraZeneca and Renalytix have formed a strategic partnership to improve the diagnosis and treatment of chronic kidney disease (CKD).
✔️ The partnership aims to leverage Renalytix's AI-powered diagnostic platform, KidneyIntelX™, to identify patients at high risk of rapid kidney function decline and allow for earlier intervention.
Why This Matters
✔️ Chronic kidney disease is a major global health issue and often goes undetected until later stages when complications arise.
✔️ Early detection and intervention are critical in slowing CKD progression and preventing kidney failure.
✔️ The collaboration between AstraZeneca and Renalytix aims to transform CKD management by providing better tools for risk assessment and targeted treatment.
KidneyIntelX diagnostic platform
✔️ KidneyIntelX is a machine learning-driven platform that analyzes a combination of blood test results, electronic health record data, and patient demographics.
✔️ This allows it to provide a highly accurate risk score for patients, indicating their likelihood of experiencing rapid kidney disease progression or needing dialysis or a kidney transplant.
AstraZeneca's Benefit
✔️ Access to KidneyIntelX allows AstraZeneca to better identify patients in clinical trials that would most benefit from their CKD treatments.
✔️ This improved patient selection enhances the potential success of their clinical trials, accelerating drug development and time to market.
Overall Impact
The partnership between AstraZeneca and Renalytix highlights the growing integration of AI and advanced diagnostics into the pharmaceutical space. This has the potential to revolutionize the way chronic diseases are managed, bringing us closer to a future of personalized medicine and improved patient outcomes.